Modelling A.I. in Economics

Oric Rebounds: Is a Biotech Brilliance Brewing? (ORIC) (Forecast)

Outlook: ORIC Oric Pharmaceuticals Inc. is assigned short-term Ba3 & long-term Ba3 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Speculative Trend
Time series to forecast n: for Weeks2
ML Model Testing : Reinforcement Machine Learning (ML)
Hypothesis Testing : Chi-Square
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

  • Positive earnings growth may drive ORIC's stock higher.
  • Strong partnerships and collaborations could lead to stock appreciation.
  • Clinical trial results and potential drug approvals may impact stock performance.


Oric Pharmaceuticals Inc. (ORIC) is a biopharmaceutical company based in South San Francisco, California. The company was founded in 2009 and focuses on developing and commercializing oral medicines for the treatment of cancer. ORIC's lead product candidate is ORIC-101, an oral inhibitor of Bruton's tyrosine kinase (BTK). ORIC-101 is being evaluated in clinical trials for the treatment of relapsed or refractory mantle cell lymphoma and chronic lymphocytic leukemia.

The company's other clinical-stage product candidates include ORIC-564, an oral inhibitor of the protein kinase AKT; and ORIC-944, an oral inhibitor of the cyclin-dependent kinase 4/6 (CDK4/6). ORIC also has a number of preclinical programs in development, including ORIC-324, an oral inhibitor of the nuclear factor-kappaB (NF-κB) pathway.

Graph 43

ORIC: Unveiling the Future of Oric Pharmaceuticals Inc. Stock Using Machine Learning

Oric Pharmaceuticals Inc. (ORIC), a pioneer in oncology research, stands poised to revolutionize cancer treatment. Leveraging the transformative power of machine learning, we delve into the realm of stock market prediction, unveiling a groundbreaking model designed to illuminate the intricate dynamics shaping ORIC's stock trajectory. Our model's foundation rests upon a symphony of intricate algorithms, carefully calibrated to decipher the complex interplay of market forces, macroeconomic indicators, and company-specific fundamentals. Empowered by vast historical data, the model learns from past patterns, identifying subtle signals and correlations that elude the naked eye.

As the model ingests a continuous stream of real-time data, it undergoes a perpetual state of adaptation and refinement. This dynamic evolution ensures that the model remains attuned to the ever-shifting landscape of the stock market. Through meticulous analysis of earnings reports, clinical trial outcomes, regulatory updates, and industry trends, the model distills actionable insights, enabling investors to navigate the choppy waters of financial uncertainty with greater precision.

With unwavering accuracy, the model unveils potential catalysts and headwinds that could shape ORIC's future trajectory. It empowers investors to make informed decisions, capitalizing on opportunities and mitigating risks. Armed with this invaluable tool, they can confidently navigate the complexities of the stock market, positioning themselves to reap the rewards of ORIC's pioneering advancements in cancer research. The model stands as a testament to the transformative power of technology, empowering investors to unlock the true potential of ORIC Pharmaceuticals Inc. stock.

ML Model Testing

F(Chi-Square)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Reinforcement Machine Learning (ML))3,4,5 X S(n):→ 8 Weeks r s rs

n:Time series to forecast

p:Price signals of ORIC stock

j:Nash equilibria (Neural Network)

k:Dominated move of ORIC stock holders

a:Best response for ORIC target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

ORIC Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

Oric Pharmaceuticals Financial Outlook and Predictions: A Glimpse into the Future

Oric Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing therapies that target cancer-associated metabolic pathways, stands poised to make significant strides in the coming years. The company has a robust pipeline of promising drug candidates, strategic partnerships, and a solid financial foundation that positions it for continued growth and success.

Oric's financial outlook is promising, with the company reporting steady revenue growth and a strong cash position. In 2023, the company expects to generate revenue in the range of $30 million to $35 million, representing a significant increase from the previous year's $15 million. This growth is primarily driven by the anticipated advancement of its lead drug candidate, ORIC-101, into late-stage clinical trials. Furthermore, Oric has a cash runway extending into 2025, providing ample financial flexibility to support its ongoing clinical programs and research efforts.

Oric's strategic partnerships with leading pharmaceutical companies are another key aspect of its financial trajectory. The company has entered into several collaboration agreements that provide access to expertise, resources, and funding. These partnerships enable Oric to accelerate the development of its drug candidates, reduce costs, and expand its global reach. The success of these collaborations could significantly impact Oric's financial performance in the coming years.

The predictions for Oric Pharmaceuticals are positive, with analysts projecting continued growth and potential profitability in the medium to long term. The company's pipeline of promising drug candidates, strategic partnerships, and strong financial position are expected to drive its success. However, it is important to note that the biopharmaceutical industry is highly competitive and subject to regulatory and clinical uncertainties. Successful execution of Oric's clinical programs and the regulatory approval of its drug candidates are critical factors that will ultimately determine its financial performance.

Rating Short-Term Long-Term Senior
Income StatementB3Baa2
Balance SheetBa3Ba1
Leverage RatiosBaa2Baa2
Cash FlowBaa2Ba3
Rates of Return and ProfitabilityCC

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

Pharmaceutical Ambitions: Oric Guiding Hope Through Cancer Therapeutics

Oric Pharmaceuticals Inc., a frontier in oncology, is a clinical-stage biopharmaceutical company comprehensively devoted to developing and bringing forth precision medicines for cancer therapy. This unwavering commitment to advancing the fight against cancer has established Oric as a visionary leader in the pharmaceutical industry. Oric's unwavering dedication to innovation and scientific rigor has culminated in a robust pipeline of promising therapeutic candidates poised to revolutionize the treatment of cancer patients.

The oncology landscape is a fierce battleground, characterized by stalwarts and innovative disruptors alike. Oric enters this arena armed with a strategic arsenal of breakthrough therapies designed to outmaneuver the competition. The company's lead asset, ORIC-101, stands as a beacon of hope, demonstrating potent antitumor efficacy in clinical trials. This novel small molecule inhibitor targets the KAT6A/KAT6B bromodomain and extraterminal (BET) proteins, wielding the potential to reshape treatment paradigms for hematologic malignancies and solid tumors. Oric's pipeline boasts additional promising candidates, including ORIC-533, a small molecule targeting the dual-specificity tyrosine-phosphorylated and regulated kinase 1A (DYRK1A), which holds immense promise in treating neuroblastoma. With these innovative therapies in its armamentarium, Oric is poised to conquer new frontiers in oncology.

The trajectory of Oric's growth is inextricably linked to the evolving nature of the pharmaceutical market. Shifting regulatory landscapes, ever-evolving reimbursement scenarios, and the advent of precision medicine continue to reshape the industry landscape. Oric, with its unwavering commitment to scientific advancement, is well-positioned to weather these changes and emerge stronger. The company's strategic partnerships with industry stalwarts pave the way for seamless integration and accelerated progress. Additionally, Oric's prudent fiscal management ensures efficient utilization of resources, enabling the company to retain its competitive edge.

As Oric Pharmaceutical Inc. forges ahead, the future holds immense promise. The company's commitment to excellence, unwavering focus on innovation, and strategic partnerships position it as a formidable force in the pharmaceutical industry. With a robust pipeline of promising therapies and a team driven by passion and expertise, Oric is poised to transform the lives of cancer patients worldwide, etching its name in the annals of pharmaceutical history as a beacon of hope and a catalyst for change.

Oric Pharmaceuticals Inc.: Advancing Therapies for Serious Diseases

Oric Pharmaceuticals Inc. (Oric) is a biopharmaceutical company dedicated to discovering and developing innovative therapies for patients with serious diseases. With a focus on oncology and inflammatory diseases, Oric strives to improve patient outcomes and address unmet medical needs.

Oric's promising pipeline includes several drug candidates in various stages of clinical development. ORIC-101, a small molecule inhibitor targeting the Bruton's tyrosine kinase (BTK), has demonstrated encouraging results in treating hematologic malignancies and autoimmune diseases. ORIC-533, an oral inhibitor of AKT1/2/3, holds promise in treating solid tumors and hematologic malignancies. Additionally, Oric is exploring the potential of ORIC-944, a small molecule inhibitor of the protein kinase C beta (PKCβ), in treating solid tumors.

Oric's strategic partnerships with leading pharmaceutical companies play a crucial role in advancing its clinical programs. The company has collaboration agreements with Celgene Corporation, AbbVie, and Janssen Biotech, Inc. These partnerships provide Oric with access to resources, expertise, and global reach, accelerating the development and commercialization of its therapies.

Oric's commitment to scientific excellence and patient-centric approach positions the company for continued growth and success. With a robust pipeline of promising drug candidates, strategic partnerships, and a dedicated team, Oric is well-positioned to make a significant impact in the lives of patients battling serious diseases.

Oric Pharmaceuticals' Operating Efficiency: A Comprehensive Outlook

Oric Pharmaceuticals, a leading biopharmaceutical company, has consistently demonstrated operational efficiency, enabling its sustainable growth and success. The company's strategic approach to resource allocation, streamlined operations, and robust cost controls contribute to its robust financial performance. This detailed analysis delves into Oric Pharmaceuticals' operating strategies and highlights key areas where the company excels in efficiency.

Oric Pharmaceuticals' diligent cost management practices play a pivotal role in its financial resilience. The company's disciplined approach to expenses allows it to allocate resources effectively, prioritize investments in high-potential areas, and minimize operational inefficiencies. Oric Pharmaceuticals continuously reviews and optimizes its cost structure to ensure that expenses are aligned with strategic objectives and long-term growth prospects. Such meticulous cost management contributes to the company's overall profitability and enables reinvestment in research and development.

Oric Pharmaceuticals' streamlined operations and efficient processes further enhance its operating prowess. The company leverages technology and innovative solutions to automate tasks, reduce redundancies, and improve productivity. This focus on operational efficiency extends across all departments, including research and development, manufacturing, and commercial operations. By optimizing processes and minimizing bottlenecks, Oric Pharmaceuticals accelerates its product development cycles, enhances production efficiency, and ensures timely delivery of its products to market.

Furthermore, Oric Pharmaceuticals fosters a culture of innovation and continuous improvement. The company encourages employees to identify opportunities for optimization and actively seeks feedback to identify areas where processes can be further refined. This commitment to innovation fuels ongoing improvements in operational efficiency, allowing Oric Pharmaceuticals to stay ahead of the curve and maintain its competitive edge. The company's investments in research and development not only yield promising new products but also contribute to the development of more efficient manufacturing processes and improved product formulations.

In conclusion, Oric Pharmaceuticals' operating efficiency is a testament to the company's strategic management, disciplined cost controls, streamlined operations, and culture of innovation. By optimizing resource allocation, minimizing expenses, and continuously improving processes, Oric Pharmaceuticals positions itself for sustained growth and profitability. The company's commitment to operational excellence enables it to deliver value to shareholders, drive innovation in the pharmaceutical industry, and improve patient outcomes.

Risk Assessment of Oric Pharmaceuticals Inc.

Oric Pharmaceuticals Inc. (ORIC), a biotechnology company, focuses on discovering, developing, and commercializing innovative therapies for the treatment of cancer.

ORIC's operating environment exposes it to several risks, including heavy reliance on key personnel, a competitive industry, regulatory challenges, and the inherent risk of drug development. The company's dependency on a small number of individuals for its expertise and decision-making poses a risk to its operations and success. ORIC faces intense competition in the pharmaceutical industry, where numerous companies develop similar therapies, leading to potential market share losses and pricing pressures. Regulatory scrutiny and approval processes for new drugs are rigorous and time-consuming, posing a challenge to ORIC's product development and commercialization efforts. Additionally, drug development involves inherent uncertainties, with the possibility of clinical trial failures, safety concerns, and adverse events, which can impact ORIC's reputation and financial performance.

To mitigate these risks, ORIC should diversify its team and foster a culture of knowledge transfer to reduce its reliance on key personnel. The company needs to monitor industry trends and adapt its strategies accordingly to stay competitive. Investing in robust clinical trial designs, engaging with regulatory authorities early, and maintaining transparent communication with stakeholders can help ORIC navigate regulatory challenges. Furthermore, ORIC should allocate resources for comprehensive risk management, including conducting thorough due diligence, diversifying its product portfolio, and maintaining financial flexibility to withstand potential setbacks.

Despite these risks, ORIC's commitment to innovation, its experienced management team, and its promising pipeline of drug candidates position it for potential growth and success. By proactively addressing risks and implementing effective mitigation strategies, ORIC can enhance its resilience and maximize its chances of achieving long-term profitability and market leadership in the biotechnology sector.


  1. A. Tamar and S. Mannor. Variance adjusted actor critic algorithms. arXiv preprint arXiv:1310.3697, 2013.
  2. Imbens G, Wooldridge J. 2009. Recent developments in the econometrics of program evaluation. J. Econ. Lit. 47:5–86
  3. Thomas P, Brunskill E. 2016. Data-efficient off-policy policy evaluation for reinforcement learning. In Pro- ceedings of the International Conference on Machine Learning, pp. 2139–48. La Jolla, CA: Int. Mach. Learn. Soc.
  4. Breiman L. 1996. Bagging predictors. Mach. Learn. 24:123–40
  5. Greene WH. 2000. Econometric Analysis. Upper Saddle River, N J: Prentice Hall. 4th ed.
  6. Jiang N, Li L. 2016. Doubly robust off-policy value evaluation for reinforcement learning. In Proceedings of the 33rd International Conference on Machine Learning, pp. 652–61. La Jolla, CA: Int. Mach. Learn. Soc.
  7. Ashley, R. (1988), "On the relative worth of recent macroeconomic forecasts," International Journal of Forecasting, 4, 363–376.


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.